Indaptus Therapeutics to Present at the Investor Summit Conference
March 22 2023 - 7:00AM
Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company
focused on discovering and developing transformative therapeutics
for patients, today announces that it will participate at the
Investor Summit Conference being held virtually on March 29, 2023.
Jeffrey A. Meckler, Chief Executive Officer will present a
corporate overview on March 29, 2023 at 10:00am ET.
Mr. Meckler will be available for one-on-one meetings throughout
the conference.
Click here to register:
https://us06web.zoom.us/webinar/register/WN_lJ3_4emFQxySbgS47V-QoQ
About Indaptus Therapeutics
Indaptus Therapeutics has evolved from more than a century of
immunotherapy advances. The Company’s novel approach is based on
the hypothesis that efficient activation of both innate and
adaptive immune cells and pathways and associated anti-tumor and
anti-viral immune responses will require a multi-targeted package
of immune system-activating signals that can be administered safely
intravenously (i.v.). Indaptus’ patented technology is composed of
single strains of attenuated and killed, non-pathogenic,
Gram-negative bacteria producing a multiple Toll-like receptor
(TLR) agonist Decoy platform. The products are designed to have
reduced i.v. toxicity, but largely uncompromised ability to prime
or activate many of the cells and pathways of innate and adaptive
immunity. Decoy products represent an antigen-agnostic technology
that have produced single-agent activity against metastatic
pancreatic and orthotopic colorectal carcinomas, single agent
eradication of established antigen-expressing breast carcinoma, as
well as combination-mediated eradication of established
hepatocellular carcinomas and non-Hodgkin’s lymphomas in standard
pre-clinical models, including syngeneic mouse tumors and human
tumor xenografts. In pre-clinical studies tumor eradication was
observed with Decoy products in combination with anti-PD-1
checkpoint therapy, low-dose chemotherapy, a non-steroidal
anti-inflammatory drug, or an approved, targeted antibody.
Combination-based tumor eradication in pre-clinical models produced
innate and adaptive immunological memory, involved activation of
both innate and adaptive immune cells, and was associated with
induction of innate and adaptive immune pathways in tumors after
only one i.v. dose of Decoy product, with associated “cold” to
“hot” tumor inflammation signature transition. IND-enabling,
nonclinical toxicology studies demonstrated safe i.v.
administration without sustained induction of hallmark biomarkers
of cytokine release syndromes, possibly due to passive targeting to
liver, spleen, and tumor, followed by rapid elimination of the
product. Indaptus’ Decoy products have also produced significant
single agent activity against chronic hepatitis B virus (HBV) and
chronic human immunodeficiency virus (HIV) infections in
pre-clinical models.
Forward-Looking Statements
This press release contains forward-looking statements with the
meaning of the Private Securities Litigation Reform Act. These
include statements regarding management’s expectations, beliefs and
intentions regarding, among other things: our expectations and
plans regarding the Phase 1 clinical trial of Decoy20, including
the timing and design thereof; the plans and objectives of
management for future operations; our research and development
activities and costs; the sufficiency of our cash, cash equivalents
and marketable securities to fund our ongoing activities; and our
assessment of financing options to support our corporate strategy.
Forward-looking statements can be identified by the use of
forward-looking words such as “believe”, “expect”, “intend”,
“plan”, “may”, “should”, “could”, “might”, “seek”, “target”,
“will”, “project”, “forecast”, “continue” or “anticipate” or their
negatives or variations of these words or other comparable words or
by the fact that these statements do not relate strictly to
historical matters. Because forward-looking statements relate to
matters that have not yet occurred, these statements are inherently
subject to risks and uncertainties that could cause our actual
results to differ materially from any future results expressed or
implied by the forward-looking statements. Many factors could cause
actual activities or results to differ materially from the
activities and results anticipated in forward-looking statements,
including, but not limited to the following: our limited operating
history; the need for, and our ability to raise, additional capital
given our lack of current cash flow; our clinical and preclinical
development, which involves a lengthy and expensive process with an
uncertain outcome; our incurrence of significant research and
development expenses and other operating expenses, which may make
it difficult for us to attain profitability; our pursuit of a
limited number of research programs, product candidates and
specific indications and failure to capitalize on product
candidates or indications that may be more profitable or have a
greater likelihood of success; our ability to obtain and maintain
regulatory approval of any product candidate; the market acceptance
of our product candidates; our reliance on third parties to conduct
our preclinical studies and clinical trials and perform other
tasks; our reliance on third parties for the manufacture of our
product candidates during clinical development; our ability to
successfully commercialize Decoy20 or any future product
candidates; our ability to obtain or maintain coverage and adequate
reimbursement for our products; the impact of legislation and
healthcare reform measures on our ability to obtain marketing
approval for and commercialize Decoy20 and any future product
candidates; product candidates of our competitors that may be
approved faster, marketed more effectively, and better tolerated
than our product candidates; our ability to adequately protect our
proprietary or licensed technology in the marketplace; the impact
of, and costs of complying with healthcare laws and regulations,
and our failure to comply with such laws and regulations;
information technology system failures, cyberattacks or
deficiencies in our cybersecurity; and unfavorable global economic
conditions. These and other important factors discussed under the
caption “Risk Factors” included in our most recent Annual Report on
Form 10-K filed with the SEC on March 17, 2023, and our other
filings with the SEC, could cause actual results to differ
materially from those indicated by the forward-looking statements
made in this press release. All forward-looking statements speak
only as of the date of this press release and are expressly
qualified in their entirety by the cautionary statements included
in this press release. We undertake no obligation to update or
revise forward-looking statements to reflect events or
circumstances that arise after the date made or to reflect the
occurrence of unanticipated events, except as required by
applicable law.
Contact: investors@indaptusrx.com
Investor Relations Contact:
CORE IRLouie Tomalouie@coreir.com
CORE IRJules Abraham (media)917-885-7378julesa@coreir.com
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Jul 2023 to Jul 2024